MetaCap

Amneal Pharmaceuticals (AMRX) vs Axsome Therapeutics (AXSM)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Amneal Pharmaceuticals (AMRX) has outperformed Axsome Therapeutics (AXSM) over the past year, gaining 76.7% versus a loss of 13.4%. Over five years, AMRX leads with a +396.9% price change compared with +250.4% for AXSM. Amneal Pharmaceuticals is the larger company by market cap ($7.36 billion vs $6.80 billion), about 1.1 times the size, while Axsome Therapeutics is growing revenue faster (+65.5% vs +8.0%).

On valuation, Amneal Pharmaceuticals trades at a lower forward P/E (17.1x vs 35.5x for Axsome Therapeutics). Amneal Pharmaceuticals converts more of its revenue into profit, with a net margin of 2.4% versus -28.7%.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

AMRX+76.74%AXSM-13.44%
+88%+35%-18%
Nov 21, 20251 yearNov 20, 2026
AMRX+357.14%AXSM+261.34%
+647%+271%-105%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

AMRX versus AXSM key metrics
MetricAMRXAXSM
Share price$21.12$129.36
Market cap$7.36B$6.80B
1-day change-1.26%-4.66%
YTD return+67.62%-29.17%
1-year return+76.74%-13.44%
5-year return+396.94%+250.38%
P/E ratio (TTM)52.80—
Forward P/E17.1335.47
EPS (TTM)$0.40$-3.03
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$3.02B$638.50M
Revenue growth (YoY)+8.05%+65.55%
Net income (latest FY)$72.06M$-183.17M
Gross margin36.88%92.56%
Operating margin13.05%-26.12%
Net margin2.39%-28.69%
52-week high$22.13$260.19
52-week low$11.71$123.00
Distance from 52-week high-4.54%-50.28%
Analyst consensusstrong_buystrong_buy
Avg. price target upside+15.01%+104.56%
Average volume3.16M865.33K
Shares outstanding348.41M52.60M
Employees8,7001,390
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • AMRX has outperformed AXSM by 90.2 percentage points over the past year.
  • Amneal Pharmaceuticals is more profitable, keeping 2.4 cents of every revenue dollar as net income versus -28.7 cents for Axsome Therapeutics.
  • Axsome Therapeutics grew revenue faster in its latest fiscal year (+65.55% vs +8.05%).

About Amneal Pharmaceuticals

AMRX stock →

Amneal Pharmaceuticals, Inc., a global biopharmaceutical company, develops, manufactures, markets, and distributes generics, injectables, biosimilars, and specialty branded pharmaceutical products in the United States, India, Ireland, and internationally. The company operates through three segments: Affordable Medicines, Specialty, and AvKARE.

Health Care · Biotechnology: Pharmaceutical Preparations · 8,700 employees

About Axsome Therapeutics

AXSM stock →

Axsome Therapeutics, Inc., a biopharmaceutical company, develops and delivers novel therapies for the management of central nervous system (CNS) disorders in the United States. The company's commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist, sigma-1 receptor agonist, aminoketone, and CYP2D6 inhibitor indicated for the treatment of major depressive disorder in adults; Sunosi (solriamfetol), a dopamine and norepinephrine reuptake inhibitor, trace amine-associated receptor 1 agonist, and 5-HT1A agonist indicated for the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea; and Symbravo (MoSEIC meloxicam rizatriptan), or AXS-07, a rapidly absorbed, multi-mechanistic, selective COX-2 inhibitor, and 5-HT1B/1D agonist indicated for the acute treatment of migraine with or without aura.

Health Care · Biotechnology: Pharmaceutical Preparations · 1,390 employees

AMRX vs AXSM FAQ

Which is bigger, Amneal Pharmaceuticals or Axsome Therapeutics?

Amneal Pharmaceuticals (AMRX) is larger, with a market capitalization of $7.36B compared with $6.80B for Axsome Therapeutics (AXSM).

Which stock has performed better over the past year, AMRX or AXSM?

AMRX returned +76.74% over the past 12 months, compared with -13.44% for AXSM (price return, excluding dividends). Past performance does not predict future results.

Are Amneal Pharmaceuticals and Axsome Therapeutics in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons